Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 4/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1055688 | 0.84 | TOP2A (0.34) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL3797462 | 0.80 | CRBN (0.36) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL1058021 | 0.77 | MEN1 (0.32) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL2435477 | 0.75 | MAPK1 (0.35) | MAPT | |
| SCHEMBL28833770 | 0.68 | CRBN (0.39) | CRBNMAPTDDB1 | |
| SCHEMBL2435501 | 0.68 | CRBN (0.32) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL1583251 | 0.66 | DDB1 (0.47) | CRBNMAPTDDB1 | |
| SCHEMBL2909916 | 0.65 | TOP2A (0.39) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL11086765 | 0.64 | TOP2A (0.46) | CRBNTOP2ATOP2BALDH1A1MAPT | |
| SCHEMBL7862920 | 0.64 | ALDH1A1 (0.42) | CRBNTOP2ATOP2BALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697344-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-09-28 | — | — | EP | disclosed |
| US-7834043-B2 | Prevent reproduct of aids virus | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
| US-20050131017-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | CRBN 3833/4885TOP2A 1571/4885TOP2B 1223/4885 |
| US-20050131017-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | CRBN 3560/4885TOP2A 1832/4885TOP2B 1352/4885 |
| US-20100249181-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | CRBN 3560/4885TOP2A 1832/4885TOP2B 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.